Dr. James Del Rosso discusses the benefits of topical JAK inhibitors over oral JAK inhibitors for the treatment of atopic dermatitis.

Lisa Swanson, MD, a board-certified dermatologist and pediatric dermatologist with Ada West Dermatology in Boise, Idaho, reviews the role that Janus kinases (JAKs) play in the inflammatory process and the benefits of inhibiting this enzyme when treating patients with atopic dermatitis. She also elaborates upon her experiences using the newly approved JAK inhibitors in her own patients. Dr. Swanson then outlines things to consider before starting patients on JAK inhibitors. 

Lisa Swanson, MD, a board-certified dermatologist and pediatric dermatologist with Ada West Dermatology in Boise, Idaho, discusses how she intends to incorporate newly approved JAK inhibitors into her atopic dermatitis treatment algorithm and her strategies for patient counseling when treating with these agents.

Raj Chovatiya, MD, PhD, Director of the Center for Eczema and Itch at the Department of Dermatology at Northwestern University Feinberg School of Medicine, discusses how he addresses questions from his patients with AD regarding potential adverse events and warnings associated with treatments for AD. 

Douglas DiRuggiero, DMSc, PA-C, discusses the exciting renaissance occurring in the realm of topical treatments for atopic dermatitis.

Matthew Zirwas, MD, provides guidance on speaking with patients with atopic dermatitis about treating their condition with topical JAK inhibitors. 

Douglas DiRuggiero, DMSc, PA-C, discusses the mechanism of action and efficacy of topical and systemic JAK inhibitors for the treatment of atopic dermatitis.

Matthew Zirwas, MD, discusses the efficacy, benefits, and safety profile of topical and systemic JAK inhibitors for the treatment of atopic dermatitis.